Screener
KAUG vs PBE
Innovator U.S. Small Cap Power Buffer ETF - August vs Invesco Biotechnology & Genome ETF
Key differences
- PBE costs 0.21% less per year.
- PBE is significantly larger than KAUG — larger funds tend to be more liquid and less likely to close.
- KAUG is classified as alternative, while PBE is equity — different risk/return profiles.
- KAUG follows a structured outcome strategy; PBE uses index tracking.
- PBE has a longer track record, which may reduce uncertainty around long-term behavior.
Side-by-side comparison
| KAUG | PBE | |
|---|---|---|
| Annual cost (TER) | 0.79% | 0.58% |
| Fund size (AUM) | $80M | $247M |
| Since | 2024 | 2005 |
| Dividend yield | 0.00% | 1.09% |
| Asset class | alternative | equity |
| Region | north america | north america |
| Strategy | structured outcome | index tracking |
| CAGR 1Y | +17.0% | +35.8% |
| CAGR 3Y | N/A | +10.3% |
| CAGR 5Y | N/A | +3.5% |
| Sharpe 3Y | N/A | 0.41 |
| Volatility 1Y | 8.09% | 18.63% |
| Max drawdown | -15.66% | -37.84% |
Green dot indicates the better value for that metric. Performance data is historical and does not predict future results.
Similar to KAUG and PBE
Explore further